Heinz-Josef Lenz, MD, discusses the significance of conducting biomarker testing in patients with metastatic colorectal cancer in accordance with the results of the phase 2 CheckMate-142 trial.
Heinz-Josef Lenz, MD
Advertisement
Articles by Heinz-Josef Lenz, MD
Heinz-Josef Lenz, MD, discusses the significance of the latest updates in the CheckMate 142 trial exploring an immunotherapy treatment combination in patients with metastatic colorectal cancer whose tumors are microsatellite instability–high or mismatch repair deficient.
Advertisement
Latest Updated Articles
Nivolumab/Ipilimumab Combination Data Promising in MSI-H/dMMR mCRCPublished: August 27th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
